Abstract: The present invention relates to an ophthalmic composition for promoting tear secretion, the composition comprising 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile or a salt thereof.

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Abstract: An image processing device includes: an acquisition unit that acquires a probability distribution of luminance of a pixel in a plurality of perspective images including the luminance of the pixel which is superposition of luminance components resulting from respective objects, based on an occurrence frequency of a perspective image in which the luminance of the pixel has respective values of a plurality of values; a distribution estimation unit that estimates a mixture distribution indicating the acquired probability distribution; a component estimation unit that estimates a component corresponding to a smallest expectation value distribution of which an expectation value is the smallest among a plurality of partial distributions that form the estimated mixture distribution, and forming at least a portion of the luminance of the pixel; a removal unit that removes the estimated component from the luminance of the pixel included in the perspective image.

Abstract: The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Abstract: A power semiconductor device includes a power semiconductor element, a controlling element, a first lead frame and a second lead frame, respectively, a first metal wire electrically connecting the power semiconductor element and the first lead frame, and a sealing body covering these components. The first lead frame includes a first inner lead having a connecting surface to which one end of the first metal wire is connected. Among surfaces of the sealing body, in a side surface, a resin inlet mark is formed in a side surface portion from which the first lead frame and the second lead frame do not project, the resin inlet mark being greater in surface roughness than another area. The resin inlet mark is formed opposite to a side where the first metal wire is positioned on the connecting surface when seen in the direction along the mounting surface.

Abstract: An image processing device includes: an acquisition unit that acquires a probability distribution of luminance of a pixel in a plurality of perspective images including the luminance of the pixel which is superposition of luminance components resulting from respective objects, based on an occurrence frequency of a perspective image in which the luminance of the pixel has respective values of a plurality of values; a distribution estimation unit that estimates a mixture distribution indicating the acquired probability distribution; a component estimation unit that estimates a component corresponding to a smallest expectation value distribution of which an expectation value is the smallest among a plurality of partial distributions that form the estimated mixture distribution, and forming at least a portion of the luminance of the pixel; a removal unit that removes the estimated component from the luminance of the pixel included in the perspective image.

Abstract: A power semiconductor device includes a power semiconductor element, a controlling element, a first lead frame and a second lead frame, respectively, a first metal wire electrically connecting the power semiconductor element and the first lead frame, and a sealing body covering these components. The first lead frame includes a first inner lead having a connecting surface to which one end of the first metal wire is connected. Among surfaces of the sealing body, in a side surface, a resin inlet mark is formed in a side surface portion from which the first lead frame and the second lead frame do not project, the resin inlet mark being greater in surface roughness than another area. The resin inlet mark is formed opposite to a side where the first metal wire is positioned on the connecting surface when seen in the direction along the mounting surface.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract: [Object] To provide: a sublimation transfer printing method of a dry developing system, particularly a dry nonmagnetic developing system, still particularly a dry nonmagnetic one -component developing system, said sublimation transfer printing method being capable of achieving a high color depth and inhibiting the staining of non-image areas of a printed product; a printed product obtained by the printing method; an intermediate recording medium which is to be used in the printing method; and a toner.

Abstract: [Object] To provide: a sublimation transfer printing method of a dry developing system, particularly a dry nonmagnetic developing system, still particularly a dry nonmagnetic one-component developing system, said sublimation transfer printing method being capable of achieving a high color depth and suppressing the staining of non-image areas of a printed product and the unevenness of printing thereof; a printed product obtained by the printing method; an intermediate recording medium which is to be used in the printing method; and a toner.

Abstract: The present invention provides an ophthalmic composition containing (A) a biguanide-based disinfectant and (B) zinc chloride. According to the present invention, an ophthalmic composition having remarkably increased disinfection effects against Acanthamoeba is provided.

Abstract: [Problem] To provide a sublimation transfer dyeing method capable of highly efficient dyeing of a product to be dyed by an electrophotographic process using a toner, and a dyed product dyed highly efficiently by the dyeing method. [Solution] A sublimation transfer dyeing method attaches a toner to an intermediate recording medium using an electrophotographic process and sublimation-transfers to a dyed product a dye contained in the toner attached to the intermediate recording medium. A dyed product dyed with high efficiency could be provided by a sublimation transfer dyeing method in which the intermediate recording medium has a density of greater than 1.00 g/cm3.

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract: A signal-processing device, which processes transparent images each expressed by transparent superimposition of a target such as an affected part and a background, includes a transparent image acquiring unit that acquires the transparent images each including the target at a plurality of times; a calculating unit that calculates a component of the transparent image originating from the target and a component of the transparent image originating from the background at a given time t among the plurality of times in association with estimated values of at least one of a distribution originating from the target and a distribution originating from the background and that evaluates consistency with the transparent images; and an updating unit that updates the estimated values of at least one of a distribution originating from the target and a distribution originating from the background at the time t based on the evaluation result.

Abstract: Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.

Abstract: A certain component of an input time series signal (hereinafter referred to as input) is assumed as a cycle time-variable time series signal and a prediction model for predicting a value of the input after the predetermined time is produced, and the value of the input after the predetermined time is predicted and outputted using the prediction model.

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

Abstract: An ophthalmic composition comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone protects various types of retinal cells from degeneration, impairment or destruction, thereby remarkably promoting the survival. Consequently, the composition exhibits a remarkable effect of preventing, ameliorating or treating various retinal diseases. In addition, the composition hardly becomes white turbid during storage.

Abstract: A certain component of an input time series signal (hereinafter referred to as input) is assumed as a cycle time-variable time series signal and a prediction model for predicting a value of the input after the predetermined time is produced, and the value of the input after the predetermined time is predicted and outputted using the prediction model.

Abstract: An apparatus (10) for irradiating a target includes a radiation source (12) for generating a radiation beam and a multiple leaf beam adjuster (16) for collimating and adjusting the shape of the radiation beam from the radiation source (12) that would be projected on the target. An image detector (17) detects generates an image signal of the target. In response to the image signal, a control module (18) generate a beam adjustment signal for controlling the beam adjuster (16), thereby enabling the radiation beam from the radiation source (12) to track the movement of the target.